Keep yourself up to date with the latest checkpoint inhibitor news. This section includes updates on clinical trials, approvals, collaboration deals, and technology advancements on checkpoint inhibitor therapy.
News and Trends 3 Mar 2023
Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor
Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted…